Market By Age Group, Education, Drugs & Devices And End Users | Forecast 2019-2027
The Europe contraceptive market is expected to proliferate at a CAGR of 6.58% during the forecast years 2019-2027.
This countries studied in this region are:
O France
O Italy
O Russia
O Germany
O the UK
O Spain
O rest of Europe
The growth of the European market can mainly be attributed to the rising cognizance among the general public regarding the importance of contraceptives. With the spurt in the population, it has become essential for the government to keep the birth-rate in check, and thus, various family planning programs have been introduced to control population expansion. To avoid unwanted pregnancies and to reduce the probability of contracting STIs, people have started using various modes of birth control. Due to technological enhancements, contraceptives have now become safer, affordable, reliable and more effective. In addition, contraceptives produced with newer advancements have been reported to show higher success rates. Women are no longer skeptical to adopt modern methods of contraception. The contraceptive market has thus boomed in the region.
The European contraceptive market can be organized on the basis of age groups, education, drugs & drivers and end users. Morning-after pills are the majorly used contraceptive drugs, whereas, condoms are the most commonly used contraceptive device.
It is imperative to adopt contraceptive techniques in order to avoid unintended pregnancies and thus maintain sexual well-being. However, risks associated with the use of contraceptives make people averse to using them. Certain contraceptives may lead to serious conditions such as blood clots, breast cancer and strokes. Misconceptions and lack of knowledge regarding the contraceptive usage is another factor restricting the market growth.
The top key players operating in the European contraceptive market are Teva Pharmaceutical Industries, Ltd., Merck & Co., Inc., Allergan, Inc., Pfizer, Inc., Agile Therapeutics, Pregna, Reckitt Benckiser PLC, Afaxys, Inc., Mayer Laboratories, Inc., Cooper Surgical, Inc., SMB Corporation, Bayer AG, Ocon Medical, Ltd., Okamoto Industries, Inc., Church & Dwight Co., Inc., Melbea and Apothecus Pharmaceutical Corporation.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. CONTRACEPTIVE
MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. MARKET
DEFINITION
2.2. PORTER’S
FIVE FORCES MODEL
2.2.1. THREAT
OF NEW ENTRANTS
2.2.2. THREAT
OF SUBSTITUTE
2.2.3. BARGAINING
POWER OF BUYERS
2.2.4. BARGAINING
POWER OF SUPPLIERS
2.2.5. THREAT
OF COMPETITIVE RIVALRY
2.3. REGULATORY
OUTLOOK
2.4. PESTEL
OUTLOOK
2.5. MARKET
ATTRACTIVENESS INDEX
2.6. MARKET
PLAYER POSITIONING
2.7. KEY
INSIGHTS
2.7.1. ORAL
CONTRACEPTIVE ARE THE MAJORLY USED CONTRACEPTIVE DRUGS
2.7.2. CONDOMS
ARE THE WIDELY USED CONTRACEPTIVES DEVICE
2.7.3. AGE
GROUP OF 15–24 YEARS ARE THE MAJOR REVENUE CONTRIBUTORS TO THE EUROPE
CONTRACEPTIVE MARKET
2.8. MARKET
DRIVERS
2.8.1. GROWING
COGNIZANCE FOR CONTRACEPTIVES
2.8.2. INCREASING
USAGE OF ORAL CONTRACEPTIVES TO EVADE UNPLANNED PREGNANCY
2.8.3. SURGE
IN THE INITIATIVES OF GOVERNMENT AND NGO
2.8.4. GROWING
AWARENESS ABOUT STD
2.9. MARKET
RESTRAINTS
2.9.1. SIDE
EFFECTS RESTRICTING THE GROWTH OF CONTRACEPTIVES
2.9.2. LIMITED
ACCESS TO CONTRACEPTIVES
2.10.
MARKET OPPORTUNITIES
2.10.1.
RISING DISPOSABLE INCOME IN EMERGING
ECONOMIES
2.10.2.
UNMET MEDICAL NEEDS IN THE
EMERGING ECONOMIES
2.10.3.
TECHNOLOGICAL ADVANCEMENTS
2.11.
MARKET CHALLENGES
2.11.1.
LACK OF ACCEPTANCE OF SOCIETY
3. CONTRACEPTIVE
MARKET OUTLOOK - BY EDUCATION
3.1. LESS
THAN HIGH SCHOOL
3.2. HIGH
SCHOOL GRADUATE
3.3. COLLEGE
GRADUATE
3.4. OTHER
COLLEGE DEGREES
4. CONTRACEPTIVE
MARKET OUTLOOK - BY AGE GROUP
4.1. 15–24
YEARS
4.2. 25–34
YEARS
4.3. 35–44
YEARS
4.4. ABOVE
44 YEARS
5. CONTRACEPTIVE
MARKET OUTLOOK - BY END USER
5.1. HOUSEHOLDS
5.2. CLINICS
5.3. HOSPITALS
6. CONTRACEPTIVE
MARKET OUTLOOK - BY DRUGS AND DEVICES
6.1. CONTRACEPTIVES
DRUGS
6.1.1. ORAL
CONTRACEPTIVE PILLS
6.1.2. INJECTABLE
CONTRACEPTIVES
6.1.3. TOPICAL
CONTRACEPTIVES
6.2. CONTRACEPTIVE
DEVICES
6.2.1. MALE
CONDOMS
6.2.2. FEMALE
CONDOMS
6.2.3. DIAPHRAGMS
6.2.4. CONTRACEPTIVE
SPONGES
6.2.5. VAGINAL
RINGS
6.2.6. SUBDERMAL
IMPLANTS
6.2.7. INTRA-UTERINE
DEVICES
6.2.7.1. COPPER
INTRA-UTERINE DEVICES
6.2.7.2. HORMONAL
INTRA-UTERINE DEVICES
7. CONTRACEPTIVE
MARKET - REGIONAL OUTLOOK
7.1. EUROPE
7.1.1. COUNTRY
ANALYSIS
7.1.1.1. GERMANY
7.1.1.2. FRANCE
7.1.1.3. THE
UNITED KINGDOM
7.1.1.4. SPAIN
7.1.1.5. ITALY
7.1.1.6. RUSSIA
7.1.1.7. REST
OF EUROPE
8. COMPETITIVE
LANDSCAPE
8.1. COMPANY
PROFILES
8.1.1. ALLERGAN
INC.
8.1.2. BAYER
AG
8.1.3. MELBEA
8.1.4. PREGNA
8.1.5. PFIZER,
INC.
8.1.6. CHURCH
& DWIGHT CO., INC.
8.1.7. AFAXYS,
INC.
8.1.8. APOTHECUS
PHARMACEUTICAL CORPORATION
8.1.9. COOPER
SURGICAL INC
8.1.10.
OKAMOTO INDUSTRIES, INC
8.1.11.
MAYER LABORATORIES, INC.
8.1.12.
AGILE THERAPEUTICS
8.1.13.
MERCK & CO., INC.
8.1.14.
RECKITT BENCKISER PLC
8.1.15.
SMB CORPORATION
8.1.16.
TEVA PHARMACEUTICAL INDUSTRIES
LTD.
8.1.17.
OCON MEDICAL LTD
9. METHODOLOGY
& SCOPE
9.1. RESEARCH
SCOPE
9.2. SOURCES
OF DATA
9.3. RESEARCH
METHODOLOGY
TABLE 1 EUROPE CONTRACEPTIVE MARKET 2019-2027 ($
MILLION)
TABLE 2 CONTRACEPTIVE MARKET PLAYER POSITIONING OUTLOOK 2017
TABLE 3 EUROPE CONTRACEPTIVE MARKET BY EDUCATION
2019-2027 ($ MILLION)
TABLE 4 EUROPE CONTRACEPTIVE MARKET BY AGE GROUP
2019-2027 ($ MILLION)
TABLE 5 EUROPE CONTRACEPTIVE MARKET BY END USER
2019-2027 ($ MILLION)
TABLE 6 EUROPE CONTRACEPTIVE MARKET BY DRUGS AND
DEVICES 2019-2027 ($ MILLION)
TABLE 7 EUROPE CONTRACEPTIVES DRUGS MARKET BY
TYPE 2019-2027 ($ MILLION)
TABLE 8 EUROPE CONTRACEPTIVE DEVICES MARKET BY
TYPE 2019-2027 ($ MILLION)
TABLE 9 EUROPE INTRA-UTERINE DEVICES MARKET BY
TYPE 2019-2027 ($ MILLION)
TABLE 10 EUROPE CONTRACEPTIVE MARKET BY COUNTRY 2019-2027
($ MILLION)
FIGURE 1 EUROPE CONTRACEPTIVE MARKET 2019-2027 ($
MILLION)
FIGURE 2 PORTER’S FIVE FORCE MODEL
FIGURE 3 EUROPE CONTRACEPTIVE MARKET BY LESS THAN
HIGH SCHOOL 2019-2027 ($ MILLION)
FIGURE 4 EUROPE CONTRACEPTIVE MARKET BY HIGH SCHOOL
GRADUATE 2019-2027 ($ MILLION)
FIGURE 5 EUROPE CONTRACEPTIVE MARKET BY COLLEGE
GRADUATE 2019-2027 ($ MILLION)
FIGURE 6 EUROPE CONTRACEPTIVE MARKET BY OTHER
COLLEGE DEGREES 2019-2027 ($ MILLION)
FIGURE 7 EUROPE CONTRACEPTIVE MARKET BY 15–24 YEARS
2019-2027 ($ MILLION)
FIGURE 8 EUROPE CONTRACEPTIVE MARKET BY 25–34 YEARS
2019-2027 ($ MILLION)
FIGURE 9 EUROPE CONTRACEPTIVE MARKET BY 35–44 YEARS
2019-2027 ($ MILLION)
FIGURE 10 EUROPE CONTRACEPTIVE MARKET BY ABOVE 44 YEARS
2019-2027 ($ MILLION)
FIGURE 11 EUROPE CONTRACEPTIVE MARKET BY HOUSEHOLDS
2019-2027 ($ MILLION)
FIGURE 12 EUROPE CONTRACEPTIVE MARKET BY CLINICS
2019-2027 ($ MILLION)
FIGURE 13 EUROPE CONTRACEPTIVE MARKET BY HOSPITALS
2019-2027 ($ MILLION)
FIGURE 14 EUROPE CONTRACEPTIVE MARKET BY CONTRACEPTIVES
DRUGS 2019-2027 ($ MILLION)
FIGURE 15 EUROPE CONTRACEPTIVES DRUGS MARKET BY ORAL
CONTRACEPTIVE PILLS 2019-2027 ($ MILLION)
FIGURE 16 EUROPE CONTRACEPTIVES DRUGS MARKET BY
INJECTABLE CONTRACEPTIVES 2019-2027 ($ MILLION)
FIGURE 17 EUROPE CONTRACEPTIVES DRUGS MARKET BY TOPICAL
CONTRACEPTIVES 2019-2027 ($ MILLION)
FIGURE 18 EUROPE CONTRACEPTIVE MARKET BY CONTRACEPTIVE
DEVICES 2019-2027 ($ MILLION)
FIGURE 19 EUROPE CONTRACEPTIVE DEVICES MARKET BY MALE
CONDOMS 2019-2027 ($ MILLION)
FIGURE 20 EUROPE CONTRACEPTIVE DEVICES MARKET BY FEMALE
CONDOMS 2019-2027 ($ MILLION)
FIGURE 21 EUROPE CONTRACEPTIVE DEVICES MARKET BY
DIAPHRAGMS 2019-2027 ($ MILLION)
FIGURE 22 EUROPE CONTRACEPTIVE DEVICES MARKET BY
CONTRACEPTIVE SPONGES 2019-2027 ($ MILLION)
FIGURE 23 EUROPE CONTRACEPTIVE DEVICES MARKET BY
VAGINAL RINGS 2019-2027 ($ MILLION)
FIGURE 24 EUROPE CONTRACEPTIVE DEVICES MARKET BY
SUBDERMAL IMPLANTS 2019-2027 ($ MILLION)
FIGURE 25 EUROPE CONTRACEPTIVE DEVICES MARKET BY
INTRA-UTERINE DEVICES 2019-2027 ($ MILLION)
FIGURE 26 EUROPE INTRA-UTERINE DEVICES MARKET BY COPPER
INTRA-UTERINE DEVICES 2019-2027 ($ MILLION)
FIGURE 27 EUROPE INTRA-UTERINE DEVICES MARKET BY
HORMONAL INTRA-UTERINE DEVICES 2019-2027 ($ MILLION)
FIGURE 28 GERMANY CONTRACEPTIVE MARKET 2019-2027 ($
MILLION)
FIGURE 29 FRANCE CONTRACEPTIVE MARKET 2019-2027 ($
MILLION)
FIGURE 30 THE UNITED KINGDOM CONTRACEPTIVE MARKET
2019-2027 ($ MILLION)
FIGURE 31 SPAIN CONTRACEPTIVE MARKET 2019-2027 ($
MILLION)
FIGURE 32 ITALY CONTRACEPTIVE MARKET 2019-2027 ($ MILLION)
FIGURE 33 RUSSIA CONTRACEPTIVE MARKET 2019-2027 ($
MILLION)
FIGURE 34 REST OF EUROPE CONTRACEPTIVE MARKET 2019-2027
($ MILLION)